Table 1 Description of the patient population at baseline
Placebo | Combined (eptinezumab 100 and 300 mg) | All treatment groups | |
|---|---|---|---|
N | 299 | 593 | 892 |
Age, mean (SD) | 43.8 (10.8) | 43.8 (10.5) | 43.8 (10.6) |
Female, n (%) | 264 (88.3) | 538 (90.7) | 802 (89.9) |
Current migraine diagnosis, n (%) | |||
Chronic migraine | 125 (41.8) | 230 (38.8) | 355 (39.8) |
Episodic migraine | 174 (58.2) | 363 (61.2) | 537 (60.2) |
Duration of diagnosis, years, mean (SD) | |||
Chronic migraine | 11.0 (10.9) | 11.7 (10.8) | 11.4 (10.8) |
Episodic migraine | 17.4 (12.1) | 16.2 (11.2) | 16.6 (11.5) |
HRQoL measure scores | |||
MSQ-RR, mean (SD) | 35.1 (17.1) | 35.7 (16.8) | 35.5 (17.0) |
MSQ-RP, mean (SD) | 50.5 (22.1) | 50.6 (21.4) | 50.6 (21.6) |
MSQ-EF, mean (SD) | 48.4 (26.6) | 49.5 (24.2) | 49.1 (25.1) |
HIT-6, mean (SD) | 66.2 (4.4) | 66.5 (4.6) | 66.4 (4.5) |
MMDs, mean (SD) | 13.9 (5.7) | 13.8 (5.5) | 13.8 (5.6) |